Lv61
2490 积分 2022-05-24 加入
Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives
1个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2个月前
已完结
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2个月前
已完结
Docetaxel in Second-Line Treatment of non—small-Cell Lung Cancer
2个月前
已完结
Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
3个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
4个月前
已完结
The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
4个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
5个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
6个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
8个月前
已完结
皖公网安备34019202002308
